{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:37Z","timestamp":1760145877242,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Istanbul University Scientific Research Projects Unit","award":["TYL-2022-38565"],"award-info":[{"award-number":["TYL-2022-38565"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and\/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated (n = 60) and Vaccinated + Previously Infected (n = 60). A commercial sVNT, the ACE2\u2013RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1\/32 titration level for both groups (p &lt; 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and\/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.<\/jats:p>","DOI":"10.3390\/v16091409","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T08:38:47Z","timestamp":1725352727000},"page":"1409","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and\/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-8616","authenticated-orcid":false,"given":"Dilan","family":"Cin","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey"},{"name":"Institute of Health Sciences, Istanbul University, 34126 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Soguksu","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-7830","authenticated-orcid":false,"given":"Meryem Merve","family":"Oren","sequence":"additional","affiliation":[{"name":"Department of Public Health, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-4194","authenticated-orcid":false,"given":"Nuray","family":"Ozgulnar","sequence":"additional","affiliation":[{"name":"Department of Public Health, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Agacfidan","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-0180","authenticated-orcid":false,"given":"Sevim","family":"Mese","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Post, N., Eddy, D., Huntley, C., van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., and Kellam, P. (2020). Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 15.","DOI":"10.1101\/2020.08.25.20178806"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Winichakoon, P., Wipasa, J., Chawansuntati, K., Salee, P., Sudjaritruk, T., Yasri, S., Khamwan, C., Peerakam, R., Dankai, D., and Chaiwarith, R. (2023). Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). Sci. Rep., 13.","DOI":"10.1038\/s41598-022-26202-1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.2000.0239","article-title":"Antibody and Virus: Binding and Neutralization","volume":"270","author":"Burton","year":"2000","journal-title":"Virology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cavlek, T.V., Stevanovic, V., Kovac, S., Borko, E., Bogdanic, M., Miletic, G., Hruskar, Z., Ferenc, T., Coric, I., and Ferenc, M.V. (2023). Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals. Antibodies, 12.","DOI":"10.3390\/antib12040061"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chvatal-Medina, M., Mendez-Cortina, Y., Patino, P.J., Velilla, P.A., and Rugeles, M.T. (2021). Antibody Responses in COVID-19: A Review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.633184"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2020.05.020","article-title":"SARS-CoV-2 Antibody Testing\u2014Questions to be Asked","volume":"146","author":"Ozcurumez","year":"2020","journal-title":"Allergy Clin. Immunol."},{"key":"ref_7","first-page":"063","article-title":"Comparison of the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Assay and Direct Binding ELISA (S-IgG) with the Cytopathic Effect Assay (CPE) in Analyzing the Neutralization Antibody of Vaccination People","volume":"7","author":"Ru","year":"2021","journal-title":"J. Clin. Immunol. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A COVID-19 Milestone Attained-A Correlate of Protection for Vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Galipeau, Y., Greig, M., Liu, G., Driedger, M., and Langlois, M.A. (2020). Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.610688"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Riepler, L., R\u00f6ssler, A., Falch, A., Volland, A., Borena, W., von Laer, D., and Kimpel, J. (2020). Comparison of Four SARS-CoV-2 Neutralization Assays. Vaccines, 9.","DOI":"10.3390\/vaccines9010013"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Souiri, A., Lemriss, S., El Maliki, B., Falahi, H., El-Fahime, E., and El-Kabbaj, S. (2023). SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization. Vaccines, 11.","DOI":"10.3390\/vaccines11030590"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/jmv.26145","article-title":"Clinical performance of different SARS-CoV-2 IgG antibody tests","volume":"92","author":"Kohmer","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1107639","DOI":"10.3389\/fimmu.2023.1107639","article-title":"Establishment of national standard for anti-SARS-CoV-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard","volume":"14","author":"Guan","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Liu, K.T., Han, Y.J., Wu, G.H., Huang, K.Y.A., and Huang, P.N. (2022). Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses, 14.","DOI":"10.3390\/v14071560"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e142362","DOI":"10.1172\/jci.insight.142362","article-title":"A Simple Protein-Based Surrogate Neutralization Assay for SARS-CoV-2","volume":"5","author":"Abe","year":"2020","journal-title":"JCI Insight"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/22221751.2020.1835448","article-title":"Validation and Clinical Evaluation of a SARS-CoV-2 Surrogate Virus Neutralisation Test (sVNT)","volume":"9","author":"Meyer","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Luo, J., Klett, J., Gabert, J., Lipp, T., Karbach, J., J\u00e4ger, E., Borte, S., Hoffmann, R., and Milkovska-Stamenova, S. (2022). A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals. Microorganisms, 10.","DOI":"10.3390\/microorganisms10091812"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lo Sasso, B., Agnello, L., Giglio, R.V., Gambino, C.M., Ciaccio, A.M., Vidali, M., and Ciaccio, M. (2022). Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-12750-z"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Santos da Silva, E., Servais, J.-Y., Kohnen, M., Arendt, V., Staub, T., the CON-VINCE Consortium, the CoVaLux Consortium, Kr\u00fcger, R., Fagherazzi, G., and Wilmes, P. (2023). Validation of a SARS-CoV-2 Surrogate Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914965"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Favresse, J., Gillot, C., Di Chiaro, L., Eucher, C., Elsen, M., Van Eeckhoudt, S., David, C., Morimont, L., Dogn\u00e9, J.-M., and Douxfils, J. (2021). Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses, 13.","DOI":"10.3390\/v13071364"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2\u2013Spike Protein\u2013Protein Interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jmv.27287","article-title":"Correlation Between a Quantitative Anti-SARS-CoV-2 IgG ELISA and Neutralization Activity","volume":"94","author":"Bartok","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cca.2021.11.023","article-title":"Long-Term Decay of Anti-RBD IgG Titers after BNT162b2 Vaccination is not Mirrored by Loss of Neutralizing Bioactivity Against SARS-CoV-2","volume":"524","author":"Malipiero","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on Therapeutic Neutralizing Antibodies Against the Novel Coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e12614","DOI":"10.1016\/j.heliyon.2022.e12614","article-title":"Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies","volume":"8","author":"Lokida","year":"2022","journal-title":"Heliyon"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e01224-20","DOI":"10.1128\/JCM.01224-20","article-title":"Clinical and Analytical Performance of An Automated Serological Test That Identifies S1\/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively","volume":"58","author":"Bonelli","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yin, Q.L., Zhang, Y.C., Lian, L.J., Qu, Y.Y., Wu, W., Chen, Z., Pei, R.J., Chen, T.Y., Sun, L.N., and Li, C. (2021). Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population. Viruses, 13.","DOI":"10.3390\/v13081508"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mouna, L., Razazian, M., Duquesne, S., Roque-Afonso, A.M., and Vauloup-Fellous, C. (2023). Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. Viruses, 15.","DOI":"10.3390\/v15020426"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jmv.27338","article-title":"Evaluation of the Correlation between the Access SARS-CoV-2 IgM and IgG II Antibody Tests with the SARS-CoV-2 Surrogate Virus Neutralization Test","volume":"94","author":"Kitagawa","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1515\/cclm-2022-0170","article-title":"The Role of Neutralizing Antibodies by sVNT after Two Doses of BNT162b2 mRNA Vaccine in a Cohort of Italian Healthcare Workers","volume":"60","author":"Infantino","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_32","first-page":"6680337","article-title":"Seroconversion and Abundance of IgG Antibodies Against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean population","volume":"19","author":"Cereceda","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-021-00523-5","article-title":"SARS-CoV-2 spike protein: A key target for eliciting persistent neutralizing antibodies","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMc2206725","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.4\/5 and BA.2.12.1 Subvariants","volume":"386","author":"Qu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron","volume":"602","author":"Alshammary","year":"2022","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1473-3099(22)00409-1","article-title":"Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant","volume":"22","author":"Higdon","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100452","DOI":"10.1016\/j.lanepe.2022.100452","article-title":"Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data","volume":"20","author":"Michlmayr","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_40","unstructured":"(2024, July 17). Global Initiative on Sharing All Influenza Data (GISAID); hCoV-19 Variants Dashboard. Available online: https:\/\/gisaid.org\/hcov-19-variants-dashboard\/."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1409\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:51Z","timestamp":1760111271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["v16091409"],"URL":"https:\/\/doi.org\/10.3390\/v16091409","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}